Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Arm Neoadjuvant Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) Concomitant With Weekly Nab-paclitaxel and Dose-dense Doxorubicin/Cyclophosphamide (ddAC) Chemotherapy for Clinical Stage I-III Triple Negative Breast Cancer

Next Previous
Trial Profile

Single Arm Neoadjuvant Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) Concomitant With Weekly Nab-paclitaxel and Dose-dense Doxorubicin/Cyclophosphamide (ddAC) Chemotherapy for Clinical Stage I-III Triple Negative Breast Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
  • Indications Advanced breast cancer; Early breast cancer; Male breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 10 Dec 2022 Results(n=66) assessing Systemic immune response to Durvalumab concomitant with neoadjuvant chemotherapy in early stage TNBC presented at the 45th Annual San Antonio Breast Cancer Symposium
  • 29 Jul 2022 Results (n=21) assessing clinical outcomes by race among african american women with stage I-III triple-negative breast cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology
  • 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top